Abstract
AbstractPancreatic cancer has an exaggerated dependence on mitochondrial metabolism, but methods to specifically target the mitochondria without off target effects in normal tissues that rely on these organelles is a significant challenge. The mitochondrial uncoupling protein 2 (UCP2) has potential as a cancer-specific drug target, and thus, we will review the known biology of UCP2 and discuss its potential role in the pathobiology and future therapy of pancreatic cancer.
Publisher
Springer Science and Business Media LLC
Reference189 articles.
1. “2022 Cancer Facts and Figures.” [Online]. Available: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html
2. Singhi, A. D., Koay, E. J., Chan, S. T., & Maitra, A. (2019). Early detection of pancreatic cancer: Opportunities and challenges. Gastoenterology, 156, 2024–2040. https://doi.org/10.1053/j.gastro.2019.01.259
3. Waters, A. M., & Der, C. J. (2018). KRAS: The critical driver and therapeutic target for pancreatic cancer. Cold Spring Harbor Perspectives in Medicine, 8(9), 1–17. https://doi.org/10.1101/cshperspect.a031435
4. . (2021). FDA Approves First KRAS Inhibitor: Sotorasib. Cancer Discover, 11(8), OF4 LP-OF4. https://doi.org/10.1158/2159-8290.CD-NB2021-0362
5. Canon, J., et al. (2019). The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature, 575(7781), 217–223. https://doi.org/10.1038/s41586-019-1694-1